NCT03772678

A Phase I Study to Evaluate LSALT Peptide

A Phase I Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose Finding Study to Evaluate the Safety and Pharmacokinetic Profile of LSALT Peptide in Healthy Participants

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Arch Biopartners Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A phase I double-blind, placebo-controlled, randomized, single and multiple ascending dose finding study to evaluate the safety and pharmacokinetic profile of LSALT peptide in healthy participants

Conditions

• None - Study is to Determine Safety in Healthy Participants

Interventions

Type	Name	Description
DRUG	LSALT peptide	novel 16 amino acid peptide
OTHER	0.9% Saline	saline

Timeline

• Start date: 2019-06-27
• Primary completion: 2020-03-31
• Completion: 2020-03-31
• First posted: 2018-12-11
• Last updated: 2024-11-29
• Results posted: 2024-11-29

Locations

1 site across 1 country: Australia